PTC Therapeutics Inc
XMUN:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
XMUN:BH3
|
US |
|
C
|
Carlsberg A/S
F:CBGB
|
DK |
|
Airtel Africa PLC
F:9AA0
|
UK |
|
M
|
Mycronic AB (publ)
F:MLT0
|
SE |
|
Aurea SA
PAR:AURE
|
FR |
|
G
|
Gold Road Resources Ltd
F:E6Q
|
AU |
|
S
|
Schlumberger NV
XHAM:SCL
|
US |
|
Meta Platforms Inc
MIL:1FB
|
US |
|
UIL Finance Ltd
LSE:UTLF
|
BM |
PTC Therapeutics Inc
PTC Therapeutics is a biotechnology company that focuses on medicines for rare diseases, especially inherited disorders that affect children and small patient groups. It develops drugs meant to treat the root cause of certain genetic conditions, then seeks approval to sell them in the United States and other markets. Its business is narrower than a big drugmaker’s: it concentrates on hard-to-treat diseases where patients have few other options. The company makes money in two main ways. First, it sells approved specialty medicines directly or through partners. Second, it earns licensing and collaboration payments from larger drug companies that help develop, market, or distribute some of its products. This mix gives PTC both product sales and partner-based revenue. What makes PTC different is its focus on rare-disease science and the specialized way those drugs reach patients. These medicines often require close work with doctors, insurers, patient groups, and regulators because the target patient populations are small and the diseases are complex. That makes PTC more like a focused rare-disease drug company than a broad pharmaceutical seller.
PTC Therapeutics is a biotechnology company that focuses on medicines for rare diseases, especially inherited disorders that affect children and small patient groups. It develops drugs meant to treat the root cause of certain genetic conditions, then seeks approval to sell them in the United States and other markets. Its business is narrower than a big drugmaker’s: it concentrates on hard-to-treat diseases where patients have few other options.
The company makes money in two main ways. First, it sells approved specialty medicines directly or through partners. Second, it earns licensing and collaboration payments from larger drug companies that help develop, market, or distribute some of its products. This mix gives PTC both product sales and partner-based revenue.
What makes PTC different is its focus on rare-disease science and the specialized way those drugs reach patients. These medicines often require close work with doctors, insurers, patient groups, and regulators because the target patient populations are small and the diseases are complex. That makes PTC more like a focused rare-disease drug company than a broad pharmaceutical seller.
Sephience Launch: The launch of Sephience for PKU drove strong initial revenue, with $111 million in its first few months and broad early uptake across patient segments.
Revenue Beat: 2025 total net product and royalty revenue was $831 million, surpassing guidance of $750–800 million.
2026 Guidance: Product revenue guidance for 2026 is $700–800 million, projecting 19–36% year-over-year growth, mostly from Sephience.
Expense Control: 2025 operating expenses came in below guidance at $728 million, and 2026 expense guidance is $680–720 million.
Cash Position: The company finished 2025 with $1.95 billion in cash, strengthened by the sale of the Evrysdi royalty.
International Expansion: Sephience is expected to reach patients in 20–30 countries by end of 2026, with meaningful contributions from Japan and Brazil in the second half.
Pipeline Progress: FDA alignment was reached for the votoplam Phase III Huntington's trial, and a new open-label study for vatiquinone is planned to support NDA resubmission.
Favorable Market Access: Payers in the U.S. have set favorable reimbursement policies for Sephience, with few access barriers and supportive refills.
